(BEAM) Beam Therapeutics - Overview

Sector: HealthcareIndustry: Biotechnology | Exchange NASDAQ (USA) | Currency USD | Market Cap: 2.260m | Total Return 12.1% in 12m

Stock Gene Editing, Therapeutics, RNA, Medicine
Total Rating 29
Risk 65
Buy Signal -1.22
Biotechnology -8.7
Biotechnology -7.1
Market Cap: 2,260m
Avg Trading Vol: 42.7M USD
ATR: 7.61%
Peers RS (IBD): 25.3
Risk 5d forecast
Volatility69.6%
Rel. Tail Risk-14.9%
Reward TTM
Sharpe Ratio0.31
Alpha-23.27
Character TTM
Beta2.091
Beta Downside1.770
Drawdowns 3y
Max DD67.74%
CAGR/Max DD-0.15
EPS (Earnings per Share) EPS (Earnings per Share) of BEAM over the last years for every Quarter: "2021-03": -3.34, "2021-06": -1.23, "2021-09": -0.42, "2021-12": -0.95, "2022-03": -1.01, "2022-06": -1.02, "2022-09": -1.56, "2022-12": -0.54, "2023-03": -1.33, "2023-06": -1.08, "2023-09": -1.22, "2023-12": 1.73, "2024-03": -1.21, "2024-06": -1.11, "2024-09": -1.17, "2024-12": -1.09, "2025-03": -1.2421, "2025-06": -1, "2025-09": -1.1, "2025-12": 2.33, "2026-03": 0,
EPS CAGR: 28.48%
EPS Trend: 32.9%
Last SUE: 0.99
Qual. Beats: 2
Revenue Revenue of BEAM over the last years for every Quarter: 2021-03: 0.006, 2021-06: 0.006, 2021-09: 0.763, 2021-12: 51.069, 2022-03: 8.432, 2022-06: 16.652, 2022-09: 15.799, 2022-12: 20.037, 2023-03: 24.208, 2023-06: 20.116, 2023-09: 17.193, 2023-12: 316.192, 2024-03: 7.41, 2024-06: 11.772, 2024-09: 14.269, 2024-12: 30.067, 2025-03: 7.47, 2025-06: 8.466, 2025-09: 9.698, 2025-12: 114.109, 2026-03: null,
Rev. CAGR: 100.31%
Rev. Trend: 2.8%
Last SUE: 0.95
Qual. Beats: 1
Risks
Technicals: volatile
Description: BEAM Beam Therapeutics March 04, 2026

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines.

The companys pipeline includes therapies for hematologic conditions like sickle cell disease and other genetic disorders such as alpha-1 antitrypsin deficiency, phenylketonuria, and glycogen storage disease type 1a. These treatments often involve gene editing or cell therapies.

Beam Therapeutics utilizes a base editing platform. The biotechnology sector focuses on developing drugs and therapies derived from living organisms.

The company also has collaborations with other pharmaceutical firms, including Pfizer Inc., Verve Therapeutics, Inc., and Orbital Therapeutics, to expand its research into various genetic diseases and RNA-based therapies. Biotechnology companies frequently engage in such partnerships to share research costs and expertise.

To deepen your understanding of BEAMs market position, consider exploring its financial ratios and competitive landscape on ValueRay.

Headlines to Watch Out For
  • Clinical trial results for lead drug candidates
  • Regulatory approval timelines for genetic therapies
  • Collaboration milestones and upfront payments from partners
  • Research and development expenses for new programs
  • Competition from other gene editing technologies
Piotroski VR‑10 (Strict, 0-10) 0.0
Net Income: -80.0m TTM > 0 and > 6% of Revenue
FCF/TA: -0.24 > 0.02 and ΔFCF/TA 7.96 > 1.0
NWC/Revenue: 838.5% < 20% (prev 1.10k%; Δ -257.4% < -1%)
CFO/TA -0.23 > 3% & CFO -345.1m > Net Income -80.0m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 13.09 > 1.5 & < 3
Outstanding Shares: last quarter (104.9m) vs 12m ago 26.69% < -2%
Gross Margin: -126.1% > 18% (prev -3.50%; Δ -12.3k% > 0.5%)
Asset Turnover: 10.81% > 50% (prev 5.75%; Δ 5.06% > 0%)
Interest Coverage Ratio: -2.87 > 6 (EBITDA TTM -74.9m / Interest Expense TTM 33.9m)
Altman Z'' -6.02
A: 0.79 (Total Current Assets 1.27b - Total Current Liabilities 96.9m) / Total Assets 1.48b
B: -1.11 (Retained Earnings -1.64b / Total Assets 1.48b)
C: -0.08 (EBIT TTM -97.2m / Avg Total Assets 1.29b)
D: -6.75 (Book Value of Equity -1.64b / Total Liabilities 242.8m)
Altman-Z'' Score: -6.02 = D
Beneish M
DSRI: none (Receivables none/none, Revenue 139.7m/63.5m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.58 (AQ_t 0.00 / AQ_t-1 0.01)
SGI: 2.20 (Revenue 139.7m / 63.5m)
TATA: 0.18 (NI -80.0m - CFO -345.1m) / TA 1.48b)
Beneish M-Score: cannot calculate (missing components)
What is the price of BEAM shares? As of March 31, 2026, the stock is trading at USD 21.90 with a total of 2,243,241 shares traded.
Over the past week, the price has changed by -12.99%, over one month by -23.05%, over three months by -21.28% and over the past year by +12.14%.
Is BEAM a buy, sell or hold? Beam Therapeutics has received a consensus analysts rating of 4.41. Therefore, it is recommended to buy BEAM.
  • StrongBuy: 10
  • Buy: 4
  • Hold: 3
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the BEAM price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 50.5 130.7%
Analysts Target Price 50.5 130.7%
BEAM Fundamental Data Overview March 30, 2026
P/S = 16.1739
P/B = 2.0258
Revenue TTM = 139.7m USD
EBIT TTM = -97.2m USD
EBITDA TTM = -74.9m USD
Long Term Debt = 154.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 14.4m USD (from shortTermDebt, last quarter)
Debt = 293.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.06m USD (from netDebt column, last quarter)
Enterprise Value = 1.31b USD (2.26b + Debt 293.9m - CCE 1.25b)
Interest Coverage Ratio = -2.87 (Ebit TTM -97.2m / Interest Expense TTM 33.9m)
EV/FCF = -3.64x (Enterprise Value 1.31b / FCF TTM -360.0m)
FCF Yield = -27.51% (FCF TTM -360.0m / Enterprise Value 1.31b)
 FCF Margin = -257.7% (FCF TTM -360.0m / Revenue TTM 139.7m)
 Net Margin = -57.24% (Net Income TTM -80.0m / Revenue TTM 139.7m)
Gross Margin = -126.1% ((Revenue TTM 139.7m - Cost of Revenue TTM 316.0m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.88 (Enterprise Value 1.31b / Total Assets 1.48b)
Interest Expense / Debt = 3.62% (Interest Expense 10.6m / Debt 293.9m)
Taxrate = 0.0% (0.0 / 244.3m)
NOPAT = -97.2m (EBIT -97.2m * (1 - 0.00%)) [loss with tax shield]
Current Ratio = 13.09 (Total Current Assets 1.27b / Total Current Liabilities 96.9m)
Debt / Equity = 0.24 (Debt 293.9m / totalStockholderEquity, last quarter 1.24b)
 Debt / EBITDA = 0.01 (negative EBITDA) (Net Debt -1.06m / EBITDA -74.9m)
 Debt / FCF = 0.00 (negative FCF - burning cash) (Net Debt -1.06m / FCF TTM -360.0m)
 Total Stockholder Equity = 1.09b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.19% (Net Income -80.0m / Total Assets 1.48b)
RoE = -7.31% (Net Income TTM -80.0m / Total Stockholder Equity 1.09b)
RoCE = -7.79% (EBIT -97.2m / Capital Employed (Equity 1.09b + L.T.Debt 154.1m))
 RoIC = -8.89% (negative operating profit) (NOPAT -97.2m / Invested Capital 1.09b)
 WACC = 12.22% (E(2.26b)/V(2.55b) * Re(13.34%) + D(293.9m)/V(2.55b) * Rd(3.62%) * (1-Tc(0.0)))
Discount Rate = 13.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.64%
 [DCF] Fair Price = unknown (Cash Flow -360.0m)
 EPS Correlation: 32.95 | EPS CAGR: 28.48% | SUE: 0.99 | # QB: 2
Revenue Correlation: 2.76 | Revenue CAGR: 100.3% | SUE: 0.95 | # QB: 1
EPS next Quarter (2026-06-30): EPS=-1.04 | Chg7d=+0.001 | Chg30d=-0.053 | Revisions Net=+5 | Analysts=13
EPS current Year (2026-12-31): EPS=-4.31 | Chg7d=+0.004 | Chg30d=-0.075 | Revisions Net=-1 | Growth EPS=-432.2% | Growth Revenue=-65.5%
EPS next Year (2027-12-31): EPS=-4.36 | Chg7d=-0.033 | Chg30d=-0.104 | Revisions Net=+1 | Growth EPS=-1.0% | Growth Revenue=+48.8%
[Analyst] Revisions Ratio: +0.71 (6 Up / 1 Down within 30d for Next Quarter)
Additional Sources for BEAM Stock Fund Manager Positions: Dataroma · Stockcircle